PCMI
TRIB

Paradigm Capital Management Inc’s Trinity Biotech TRIB Stock Holding History

Paradigm Capital Management Inc’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-10,000
Closed -$588K – 194
2015
Q4 		$588K Buy
+10,000
New +$590K 0.07% 140

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Paradigm Capital Management Inc's TRIB Position: Q1 2016 in Review

Paradigm Capital Management Inc sold out of Trinity Biotech (TRIB) in Q1 2016, closing a stake of 10,000 shares — an estimated $588K sold.

Paradigm Capital Management Inc first reported a position in TRIB in Q4 2015 and held it in 1 quarter. The position peaked at $588K in Q4 2015. 79 funds tracked by Wall St. Rank hold TRIB as of Q1 2016.

  • Paradigm Capital Management Inc reported no remaining Trinity Biotech position as of Q1 2016 after selling out during the quarter.
  • Paradigm Capital Management Inc sold 10,000 Trinity Biotech shares in Q1 2016, an estimated $588K.
  • Paradigm Capital Management Inc first reported a position in Trinity Biotech in Q4 2015 and held it in 1 quarter.
  • Paradigm Capital Management Inc's Trinity Biotech position peaked at $588K in Q4 2015.
  • 79 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2016.

Based on Paradigm Capital Management Inc's 13F filing for Q1 2016, filed 12 May 2016.